20.1 Follow-Up Intervals and Surveillance

Domain V Evaluation asks a deceptively simple question: when do you see this person again, and what are you measuring? A complete FNP plan names the drug or the counseling and the clock. “Return as needed,” “follow up PRN,” and “come back if you feel worse” are not plans. They dump the surveillance job onto a patient who may not know which symptom is an emergency and who may not be able to get a same-week slot. On FNP-BC, the next interval is as testable as the next prescription.

The interval is not a personality preference. It is set by five facts: how soon the intervention can harm, how soon you can measure benefit, how dangerous the next event is, whether the clock is a screening clock measured in years, and whether monitoring itself is the treatment. Process the stem that way and the numbers become memorable instead of a flashcard pile.

Days to a few weeks: the new-start harm window

New antihypertensive therapy. After you start or change a blood-pressure drug, bring the adult back in about 1 month until blood pressure is at goal. That is the ACC/AHA-style titration clock, not a wellness-visit clock. Lifestyle-only management of stage 1 hypertension with lower cardiovascular risk can wait 3–6 months. Stage 2 readings, symptomatic hypertension, or a frail older adult who just started a diuretic may need 1–2 weeks. Once controlled, stretch to 3–6 months. “Start amlodipine and see you next year” fails Evaluation even if the drug choice was correct.

New antidepressant. The first visit after a selective serotonin reuptake inhibitor or similar start is in 1–4 weeks, often at the short end for adolescents and young adults. That visit is a safety visit, not the 8-week efficacy visit. Early activation, insomnia, agitation, and suicidal thinking can appear before mood improves. The Food and Drug Administration boxed warning on suicidality in people younger than 25 is why you do not say “the medicine takes two months — call if you are worse.” Ask directly about suicidal ideation, means, and hopelessness. Confirm the patient is taking the capsule. Then you may use the 4–8 week window to judge whether the dose is working.

Warfarin. International normalized ratio (INR) is checked in days after a start or a dose change — commonly about 2–3 days — then repeatedly until two consecutive values sit in range, then weekly, then every 2 weeks, then about monthly when stable. A new venous-thromboembolism start with “INR at your annual physical” is how you create a bleed or a clot. Antibiotics, amiodarone, dietary collapse, and heart-failure flares reset the clock back to days. Chapter 19 covers target ranges; this section owns the calendar.

ACE inhibitor, angiotensin-receptor blocker, and mineralocorticoid-antagonist labs. Check serum creatinine and potassium in 1–2 weeks after start or up-titration, sooner if the patient is volume-depleted, on a diuretic plus a nonsteroidal anti-inflammatory drug, or already near hyperkalemia. A creatinine rise of about 30% can be an expected hemodynamic change; a larger jump, a falling estimated glomerular filtration rate that does not stabilize, or potassium that climbs into a dangerous range is a reason to hold, hydrate, stop the offending combination, or refer — not a reason to “give it three months.” The same 1–2 week lab clock applies when you add spironolactone for resistant hypertension or heart failure.

Months: chronic disease you are actively changing

Type 2 diabetes. If you started, stopped, or substantially changed glucose-lowering therapy, reassess in about 3 months. Glycated hemoglobin (A1C) reflects roughly 90 days of red-cell glycation. Ordering A1C 10 days after a metformin start does not evaluate the new plan. If the patient uses continuous glucose monitoring, time-in-range can move faster than A1C, but the clinical review still belongs on a weeks-to-months cadence, not a “see me PRN” cadence.

Stable type 2 diabetes at goal. Recheck every 3–6 months. American Diabetes Association language is at least twice yearly when the patient is meeting goals on stable therapy, and about quarterly when therapy is changing or goals are not met. Do not use the practice-bank size, a school mnemonic, or “the patient is busy” to invent a 12-month A1C for someone whose last value was 9.4%.

Other month-scale clocks you should be able to name: thyroid-stimulating hormone about 6–8 weeks after a levothyroxine change; lipids about 4–12 weeks after a statin start or dose change; heart-failure volume and electrolytes days to weeks after a diuretic change, then regularly; depression symptom scores at the early safety visit and again when you judge response.

Years: screening is not disease surveillance

Cervical screening uses years. Average-risk ages 21–29: cytology every 3 years. Ages 30–65: primary high-risk HPV every 5 years, cotesting every 5 years, or cytology every 3 years. Stop after 65 when prior screening was adequate and there is no high-grade history. Stop after hysterectomy for benign disease if the cervix is gone and there is no dysplasia history. Annual cytology on a 36-year-old with a normal cotest last year is low-value care dressed up as diligence.

Bone-density testing uses years. Screen women 65 and older, and younger postmenopausal women whose risk equals that of a 65-year-old. Repeating a DXA in 6 months to “see if alendronate worked” is the wrong modality and the wrong clock. Two years is a common minimum interval; people well above the treatment threshold can wait longer.

Abdominal aortic aneurysm screening is one abdominal ultrasound in men 65–75 who have ever smoked. It is not an annual study, not a screen for every 70-year-old woman in the waiting room, and not a CT angiogram “while we are here.”

Colorectal cancer prevention in average-risk adults now starts at age 45 (USPSTF). A normal, complete colonoscopy is typically repeated in 10 years. Stool-based programs have different clocks (annual FIT; multitarget stool DNA on a shorter multi-year interval). Do not apply the 10-year rule to a poor-prep study, a first-degree-relative history that shortens the interval, or a cancer survivor (below).

Seven days after the hospital or emergency department

High-risk transitions — heart-failure exacerbation, chronic-obstructive-pulmonary-disease flare, new insulin, acute coronary syndrome, elderly polypharmacy, a suicide attempt — need primary-care follow-up within 7 days, not “when the cardiologist can see you in six weeks.” Transitional-care models also expect early outreach (often within 2 business days) and a visit inside 7 or 14 days depending on complexity. The visit is bottle-by-bottle medication reconciliation, volume and symptom review, and written red flags. Chapter 8.3 taught the handoff. This section scores whether the loop actually has a date.

“PRN” is not a plan

Write four things: what you will measure, when, who initiates contact, and which red flags come in earlier. “RTC PRN” fails all four. A parent of a wheezing preschooler needs the 48-hour check and the “go to emergency care if…” list. A man starting warfarin needs the INR date, not a hope that the anticoagulation clinic will find him.

Survivorship surveillance is not primary prevention

A breast-cancer survivor is not “average-risk mammography.” Imaging of the remaining breast or chest wall follows oncology intervals. A colon-cancer survivor’s next colonoscopy is a surveillance interval from the surgeon or gastroenterologist, not the 10-year average-risk clock. After hysterectomy for cervical intraepithelial neoplasia, vaginal-cuff cytology can still be indicated — the “no cervix, stop screening” rule applies to benign hysterectomy. Late effects have their own clocks: anthracycline cardiomyopathy, pelvic-radiation bowel disease, tamoxifen and endometrial bleeding, aromatase-inhibitor bone loss. If the stem says “history of cancer,” do not paste the USPSTF average-risk table.

When more frequent monitoring is the intervention

Some patients get better because someone is watching a number often enough to act.

• Heart-failure daily weights. Call for about 2–3 pounds in a day or 5 pounds in a week (or the threshold you documented). The scale is the diuretic adjustment.
• INR. The next dose is the last INR.
• Unstable asthma. A peak-flow or symptom diary plus early contact is how you catch the exacerbation before the emergency department.
• Continuous glucose monitoring. A 2-week download can change insulin when A1C cannot yet.
• Home blood-pressure logs during the month you are titrating.

These tasks sit on the Evaluation / Implementation seam. ANCC can code the item either way. Your job is to put the measurement on the calendar instead of hoping the portal message arrives in time.

Three afternoon clocks to rehearse. A 52-year-old starts lisinopril 10 mg: chemistry in 1–2 weeks, blood pressure in about 1 month. A 19-year-old starts sertraline: a 1–2 week safety contact, not a 3-month “med check.” A 67-year-old starts warfarin after venous thrombosis: INR in days. A 70-year-old man who smoked and never had aortic imaging: one ultrasound, then stop screening if it is normal. If you cannot name the next date, you have not finished the visit.